Valenzuela TW, Elguero PE

Language: Spanish
References: 22
Page: 11-17
PDF size: 87.03 Kb.

ABSTRACT

Introduction: Interleukin-6 is involved in atherogenesis and atherothrombotic most catastrophic phenomenon; peripheral arterial ischemia is one of the most frequent causes of limb amputation. The aim of this study was to evaluate the prognosis of high levels of interleukin-6 event of amputation in peripheral arterial ischemia. Objective: This paper aims to demonstrate that high levels of interleukin-6 can be considered as prognostic factor for amputation in acute peripheral arterial ischemia. Therefore it is of core importance to know and be aware that by measurement of interleukin-6 can identify the prognosis and outcome of patients. Material and methods: The study that is planned is of type: a prospective, longitudinal, comparative and analytical, which will be held in the Emergency Department of the Regional Hospital «Lic. Adolfo López Mateos» degree in a period January 2009 to October 2010. It will work with both male and female patients, including 18 years to 85 years who have acute peripheral arterial ischemia who enter the emergency area. Results: This study found that average age was 69 years, with a percentage of 62.5% men and 32.5% women, so an average of interleukin 6 was 13.5% for amputation. Conclusions: During the study found that IL-6 levels › 10 pg/mL in acute peripheral arterial ischemia were significantly associated with amputation more events during hospitalization.

REFERENCES

1. Bowlin SJ, Madalie JH et al. Epidemiology of intermittent claudication in middle-aged men. Am J Epidemiol 1994; 140: 418-430.

2. Criqui MH, Denember JO, Langer Rd et al. The epidemiology of peripheral disease. Vasc Med 1997: 221-226.

3. Dormandy J, Mahir M et al. Fate of the patients chronic ischemia. 1989; 30-50.

4. Gisson RJ, Smith S. Animal American Hearth Association Clinical platic.

5. Libby P, Ridker P, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.

6. Amstrong E, Morrow D, Sabatine M. Inflammatory biomarkers in acute coronary syndromes. II: Acute phase reactant and biomarkers of endothelial cell activation. Circulation 2006; 113: e152-e155.

7. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.

8. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002; 105: 1890-1896.

9. Levi M, van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004; 109: 2698-2704.

10. Kerr R. Interleukin-6 and haemostasis. Br J Haematol 2001; 115: 3.

11. Murabito JM, Evans JC, Nieto K et al. Prevalence and clinical correlates of peripheral arterial disease in the Framingham off spring study. Am Heart J 2002; 143: 961-965.

12. Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc 1999; 47 (10): 1255-1256.

13. Águila MR, Marquina RM. Acta Médica Grupo Ángeles. 2007; 5 (4): 192-208.

14. Sánchez VKB, Ayala GF, Ocampo LCR, Balcazar VR. Acta Médica Grupo Ángeles 2007; 5 (3).

15. Serrano HFJ, Martín CA. www.revespcardiol.org

16. Smith GD, Shipley MJ, Rose G. Intermittent claudication, heart disease risk factors and mortality. The Whitehall Study. Circulation 1990; 82: 1925-1931.

17. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin-6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 2001; 286: 2107-2113.

18. Hartford M, Wiklund O, Mattsson HL, Perers E, Person A, Herlitz J et al. CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the earlyphase of acute coronary syndromes and long-term follow-up. Int J Cardiol 2006; 108: 55-62.

19. Vitale C, Gebara O, Mercuro G, Wajngarten M, Silvestri A, Rossini P et al. Value of C-reactive protein levels and interleukin-6 in predicting levels in women at increased cardiovascular risk. Maturitas 2005; 50: 239-246.

20. Ueda K, Takahashi M, Ozawa K, Kinoshita M. Decreased soluble interleukin-6 receptor in patients with acute myocardial infarction.

21. Fernández VV, Matos DM, Maeso, Sancho SJ. Embolias de extremidades superiores. Rev Española Angiol Cirg Vasc 1998; XL (3): 93.

22. Martínez RE, Paz JJ. Trastornos circulatorios en cirugía. Reperfusión en pacientes revascularizados de extremidades. Educación e Investigación Clínica 1994; 1 (3): 60-61.